Drug Type Small molecule drug |
Synonyms Prilinostat Mesylate, Purinostat mesylate |
Target |
Action inhibitors |
Mechanism HDAC inhibitors(Histone deacetylase inhibitors), HDAC1 inhibitors(Histone deacetylase 1 inhibitors), HDAC2 inhibitors(Histone deacetylase 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePhase 2/3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diffuse Large B-Cell Lymphoma | Phase 3 | China | 22 Mar 2024 | |
Cutaneous T-Cell Lymphoma | Phase 2 | China | 14 Apr 2024 | |
Peripheral T-Cell Lymphoma | Phase 2 | China | 14 Apr 2024 | |
Refractory Multiple Myeloma | Phase 2 | China | 25 Mar 2024 | |
Relapse multiple myeloma | Phase 2 | China | 25 Mar 2024 | |
Diffuse large B-cell lymphoma recurrent | Phase 2 | China | 08 Nov 2022 | |
Diffuse large B-cell lymphoma refractory | Phase 2 | China | 08 Nov 2022 | |
Acute Lymphoblastic Leukemia | Phase 2 | China | 30 Jan 2022 | |
Multiple Myeloma | Phase 2 | China | 30 Jan 2022 | |
T-Cell Leukemia | Phase 2 | China | 30 Jan 2022 |
NCT05563844 (ASCO2024) Manual | Phase 2 | Diffuse Large B-Cell Lymphoma double-expressor (DEL) | TP53 abnormal | 28 | (mjahtifyxl) = jjknecjach wznfawomlz (wzviogkuzj, 38.4 - 88.2) View more | Positive | 02 Jun 2024 | |
(mjahtifyxl) = kohdrnxbzq wznfawomlz (wzviogkuzj, 46.2 - 95.0) | |||||||
Phase 1 | 18 | (nekvlxhkbs) = tumxhmntzg cjilwfsaja (xeknvwbmdk ) View more | Positive | 09 Jun 2023 |